Predicting Disease Progression in Atrial Fibrillation: A Multiparametric Approach for Prognostic Marker Identification and Personalized Patient Management

This project leverages artificial intelligence (AI) to decipher Atrial Fibrillation (AF) progression and optimize treatment strategies. By recruiting a diverse cohort of 322 AF patients, we will gather a robust multiparametric dataset including clinical, genetic, electrocardiographic, and echocardiographic data. Harnessing AI, we will extract and correlate hidden components within ECG-obtained P-wave data and echocardiographic studies with atrial fibrosis, culminating in an atrial fibrosis score (AFS). The AFS will non-invasively predict fibrosis extent and AF clinical progression, including metrics like rehospitalization, cardiac morbidity, and mortality. Ultimately, this endeavor aims to improve AF patient management, significantly reducing healthcare costs, and enhancing patient quality of life.

开始日期2025-09-03

申办/合作机构

IRCCS Policlinico San Donato

[+2]

NCT06647927 / Not yet recruitingN/AIIT

Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis

This research makes several significant contributions to the field of BrS. It employs advanced genetic sequencing techniques to develop a genetic signature to improve the accuracy and efficiency of BrS diagnosis. The identification of specific biomolecular profiles and genetic signatures enhances our understanding of the syndrome's molecular mechanisms, facilitating targeted therapies and refined risk stratification. These advancements optimize patient care by enabling personalized treatment plans and risk assessment. Overall, this research adds value by advancing diagnostic methods, providing molecular insights, optimizing patient care, and positively impacting public health outcomes in BrS.

开始日期2024-10-01

申办/合作机构

IRCCS Policlinico San Donato

[+2]

NCT06372509 / RecruitingN/AIIT

A Proteomic Analysis for Understanding the Link Between Migraine and Cardiovascular Disease

This is a multicenter, prospective observational study. Will be collecting data from 90 consecutive patients (aged 25- 60 years ) with and without migraine admitted at our Hospital. Primary aim of the study will be to assess the correlation between migraine and proteomic profiling of plasma and their possible correlation with known cardio and cerebrovascular disease and Cardiovascular (CV) risk factors.

开始日期2024-04-03

申办/合作机构

Centro Cardiologico Monzino SpA

[+1]

100 项与 IRCCS Policlinico San Donato 相关的临床结果

登录后查看更多信息

0 项与 IRCCS Policlinico San Donato 相关的专利（医药）

登录后查看更多信息

4,167

项与 IRCCS Policlinico San Donato 相关的文献（医药）

2024-12-31·Journal of Dermatological Treatment

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals

Article

作者: Sena, Paolo ; Foti, Antonio ; Di Nicola, Matteo R. ; Bianchi, Vittoria G. ; Malagoli, Piergiorgio ; Costanzo, Antonio ; Mercuri, Santo R. ; Narcisi, Alessandra ; Paolino, Giovanni ; Locatelli, Andrea Gustavo ; Carugno, Andrea ; Valenti, Mario

BACKGROUNDGenital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area.OBJECTIVEto evaluate the efficacy of tralokinumab in AD patients with genital involvement.METHODSAdult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16.RESULTSout of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores.CONCLUSIONdespite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.

2024-12-31·Renal Failure

Assessing the role of Chemokine (C–C motif) ligand 14 in AKI: a European consensus meeting

Article

作者: Coelho, Sílvia ; Prowle, John R. ; Meyer, Alain ; Zarbock, Alexander ; Arndt, Christian ; Koyner, Jay L. ; Ostermann, Marlies ; Joannidis, Michael ; Garcia-Montesinos de la Peña, Manuel ; Pertica, Nicoletta ; Harenski, Kai ; Koch, Christian ; Baldira Martinez de Irujo, Jaume ; Lobaz, Steven ; Echeverri, Jorge ; Silversides, Jon ; di Girolamo, Luca ; Forni, Lui G. ; Jorge-Monjas, Pablo

BACKGROUNDUrinary Chemokine (C-C motif) ligand 14 (CCL14) is a biomarker associated with persistent severe acute kidney injury (AKI). There is limited data to support the implementation of this AKI biomarker to guide therapeutic actions.METHODSSixteen AKI experts with clinical CCL14 experience participated in a Delphi-based method to reach consensus on when and how to potentially use CCL14. Consensus was defined as ≥ 80% agreement (participants answered with 'Yes', or three to four points on a five-point Likert Scale).RESULTSKey consensus areas for CCL14 test implementation were: identifying challenges and mitigations, developing a comprehensive protocol and pairing it with a treatment plan, and defining the target population. The majority agreed that CCL14 results can help to prioritize AKI management decisions. CCL14 levels above the high cutoff (> 13 ng/mL) significantly changed the level of concern for modifying the AKI treatment plan (p < 0.001). The highest level of concern to modify the treatment plan was for discussions on renal replacement therapy (RRT) initiation for CCL14 levels > 13 ng/mL. The level of concern for discussion on RRT initiation between High and Low, and between Medium and Low CCL14 levels, showed significant differences.CONCLUSIONReal world urinary CCL14 use appears to provide improved care options to patients at risk for persistent severe AKI. Experts believe there is a role for CCL14 in AKI management and it may potentially reduce AKI-disease burden. There is, however, an urgent need for evidence on treatment decisions and adjustments based on CCL14 results.

2024-12-01·The American Journal of Cardiology

Eight-Year Outcomes of Patients With Reduced Left Ventricular Ejection Fraction Who Underwent Transcatheter Aortic Valve Replacement With a Self-Expanding Bioprosthesis

Article

作者: Montorfano, Matteo ; Ferrara, Erica ; Angelillis, Marco ; Gorla, Riccardo ; Merlanti, Bruno ; Toselli, Marco ; Giannini, Cristina ; Massussi, Mauro ; De Felice, Francesco ; Chin, Diana ; De Marco, Federico ; Chizzola, Giuliano ; Nicolini, Elisa ; Bedogni, Francesco ; Nazzaro, Marco Stefano ; Palmerini, Tullio ; De Carlo, Marco ; Stio, Rocco ; Paolucci, Luca ; Adamo, Marianna ; Bruschi, Giuseppe ; Regazzoli, Damiano ; Bellini, Barbara ; Iadanza, Alessandro ; Poli, Arnaldo ; Musto, Carmine ; Pennacchi, Mauro ; Gabrielli, Domenico

Data deriving from patients who underwent TAVR between 2007 and 2017 in 13 Italian centers were prospectively collected. Patients were stratified in those with normal LVEF and reduced LVEF. The latter was further classified according to ischemic or nonischemic etiology. The primary end point was a composite of all-cause death and rehospitalizations; the secondary end points were the isolated composers of the primary end point and cardiac death. Overall, 2,626 patients were included in the analysis: 68.1% with normal LVEF and 31.9% with reduced LVEF. At 8 years, reduced LVEF was significantly associated with the primary end point (adjusted hazard ratio 1.17, 95% confidence interval 1.06 to 1.29). Consistent findings were evident for the composite end point. No differences in these trends were found at the 30-day landmark analyses. Compared with nonischemic etiology, ischemic reduced LVEF was associated with an increased risk of cardiac death (adjusted hazard ratio 1.43, 95% confidence interval 1.02 to 2.02). In conclusion, patients with reduced LVEF who underwent TAVR are exposed to a progressively increased risk of death and rehospitalizations, even at very long-term follow-up.

100 项与 IRCCS Policlinico San Donato 相关的药物交易

登录后查看更多信息

100 项与 IRCCS Policlinico San Donato 相关的转化医学

登录后查看更多信息